LA JOLLA, Calif. — September 28, 2026

MediciNova, Inc. reported topline results from the randomized, double-blind, placebo-controlled MN-001-NATG-202 Phase 2 clinical trial evaluating MN-001 (tipelukast) in patients with hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The 24-week proof-of-concept study enrolled 40 patients and evaluated the investigational oral small-molecule therapy for effects on lipid parameters, liver fat, body weight, safety and tolerability. MediciNova reported a statistically significant increase in HDL-C and HDL-P at Week 24, while triglycerides showed a statistically significant reduction versus placebo at Week 4. At Week 24, triglycerides remained numerically lower with MN-001, although the between-group difference was not statistically significant. The company also reported numerical improvements in liver fat and body weight, with MN-001 generally well tolerated and no drug-related serious adverse events reported.

MN-001 Shows Changes in Triglycerides and HDL Measures

MN-001 produced an early reduction in serum triglycerides and significant improvements in HDL-related measures. At Week 4, mean triglycerides decreased by 54.7 mg/dL (26.05%) from baseline in the MN-001 group compared with a 23.8 mg/dL (11.54%) reduction with placebo, representing a 30.96 mg/dL greater decrease with MN-001 and a statistically significant difference (p=0.015). By Week 24, triglycerides had decreased by 45.8 mg/dL (21.78%) with MN-001 versus 14.4 mg/dL (6.97%) with placebo, although the between-group difference was not statistically significant (p=0.113). HDL-C increased by 3.3 mg/dL (8.39%) with MN-001 while declining by 2.4 mg/dL with placebo, producing a statistically significant between-group difference of 5.7 mg/dL (p=0.0048). HDL-P increased by 3.62 µmol/L (11.80%) with MN-001 compared with a 0.9 µmol/L decline with placebo, with a significant between-group difference of 4.52 µmol/L (p=0.018).

Liver Fat and Body Weight Show Numerical Improvement

The Phase 2 study also identified numerical changes in liver fat and body weight, although these findings did not reach statistical significance between treatment groups. At Week 24, the mean controlled attenuation parameter (CAP) score measured using FibroScan decreased by 14.1 dB/m (4.24%) from baseline with MN-001 compared with a 4.3 dB/m (1.27%) reduction with placebo. The resulting between-group difference of 9.7 dB/m was not statistically significant (p=0.2438). Mean body weight decreased by 4.91 pounds (2.28%) with MN-001 compared with 0.55 pounds (0.25%) with placebo, corresponding to a 4.36-pound greater reduction with MN-001 (p=0.082). MediciNova said MN-001 demonstrated a generally favorable safety and tolerability profile, with treatment-related adverse events described as mild to moderate and no drug-related serious adverse events reported during the study. Because the trial involved only 40 patients and was designed as an exploratory proof-of-concept study, the findings require confirmation in larger clinical studies.

Advertisement

cGxPJobs Banner

QIAGEN Addresses Rapid Bloodstream Infection Testing Needs

Bloodstream infections can progress to sepsis, making rapid identification of infectious pathogens an important component of clinical evaluation. QIAGEN cited U.S. Centers for Disease Control and Prevention estimates that approximately 1.7 million U.S. adults develop sepsis each year, with at least 350,000 dying during hospitalization or being discharged to hospice. The company said faster identification of causative pathogens and resistance markers can provide clinicians with information relevant to treatment decisions, although molecular detection results are intended to be interpreted in conjunction with other clinical and laboratory findings. The new FDA clearance gives U.S. laboratories access to the complete QIAstat-Dx bloodstream infection portfolio and broadens the platform’s role in syndromic molecular diagnostics.

Source MediciNova press release